• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Iterum Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    5/19/25 7:15:09 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ITRM alert in real time by email
    8-K
    false000165932300-000000000016593232025-05-132025-05-13

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 13, 2025

     

     

    Iterum Therapeutics plc

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Ireland

    001-38503

    Not applicable

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    3 Dublin Landings

    North Wall Quay

     

    Dublin 1, , Ireland

     

    Not applicable

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: +353 1 6694820

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Ordinary Shares, par value $0.01 per share

     

    ITRM

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 1.01 Entry into a Material Definitive Agreement.

    As previously disclosed, pursuant to a license agreement, dated November 18, 2015, by and among Iterum Therapeutics plc (the “Company”), Iterum Therapeutics International Limited (“ITIL”) and Pfizer Inc. (“Pfizer” and such agreement, the “Pfizer License Agreement”), ITIL agreed to make a regulatory milestone payment of $20.0 million to Pfizer (the “Milestone Payment”) upon the approval of oral sulopenem for commercial sale in the United States by the U.S. Food and Drug Administration (“FDA”). The Company had the option to deliver notice of its election to defer such payment for up to two years from the date of such approval and have a promissory note issued by ITIL in the amount of the Milestone Payment to Pfizer (the “Note”) within 30 calendar days of such approval. On October 25, 2024, the Company received FDA approval for ORLYNVAH™ (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiellapneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options. On October 28, 2024, the Company notified Pfizer that it was electing to defer payment of the Milestone Payment for two years, or until October 25, 2026 (such period, the “Deferral Period”), and delivered the Note to Pfizer.

    On May 13, 2025, the Company and ITIL entered into an amended and restated promissory note (the “A&R Note”) and a letter agreement relating to the A&R Note and amending the Pfizer License Agreement in connection therewith (the “Letter Agreement”). The A&R Note extends the Deferral Period by an additional three years, or until October 25, 2029 (the “Extended Deferral Period”). In connection with the extension to the Deferral Period, ITIL agreed in the A&R Note to increase the annual rate of interest from eight percent (8%) to ten percent (10%) on a daily compounded basis during the Extended Deferral Period, beginning on October 26, 2026. ITIL also agreed that it would not, directly or indirectly, (1) create, incur, assume, guaranty or otherwise become liable for any indebtedness that is senior in right of payment to the A&R Note, except for indebtedness incurred with the consent or waiver of Pfizer, or (2) create, grant or incur any lien on any of its property or assets, subject to specified exceptions (including liens securing permitted indebtedness and liens incurred with the consent or waiver of Pfizer). Pursuant to the Letter Agreement, in consideration of Pfizer entering into the A&R Note, ITIL agreed to pay to Pfizer a non-refundable, non-creditable transaction fee and to pay Pfizer’s reasonable and documented out-of-pocket legal expenses in connection therewith (together, the “Pfizer Transaction Fees”), with no further payments obligated to be made upon execution. The Company has guaranteed all of the amounts payable by ITIL under the terms of the Pfizer License Agreement and the related Letter Agreement, which includes the Pfizer Transaction Fees, pursuant to the guarantee delivered by the Company to Pfizer on November 18, 2015.

    The A&R Note incorporates other material terms of the Note. ITIL has the right to prepay the unpaid principal balance of the A&R together with accrued and unpaid interest at any time without premium or penalty. Pursuant to the terms of the A&R Note, ITIL may (i) assign the A&R Note to an affiliate of ITIL; (ii) designate one of its affiliates to perform its obligations thereunder; or (iii) assign the A&R Note in the event of a change of control, provided that in the case of clauses (i) and (ii) ITIL is not relieved of any liability thereunder. Pursuant to the terms of the Pfizer License Agreement, if a change of control of ITIL or the Company occurs during the Deferral Period, Pfizer may, in its sole discretion and at its sole option, declare the Milestone Payment to be immediately due and payable together with all interest accrued under the A&R Note.

    The foregoing descriptions of the A&R Note and the Letter Agreement are qualified in their entirety by reference to the full text of the A&R Note and the Letter Agreement, copies of which the Company intends to file as exhibits to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

    The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference.

    Item 7.01 Regulation FD Disclosure.

    The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.

    On May 19, 2025, the Company issued a press release announcing that the Company, ITIL and Pfizer had entered into the A&R Note and the Letter Agreement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and Exhibit 99.1 attached hereto is “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended.


     

     

    Item 9.01 Financial Statements and Exhibits.

    Exhibit No.

    Description

    99.1

    Press Release of Iterum Therapeutics plc, dated May 19, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Iterum Therapeutics plc

     

     

     

     

    Date:

    May 19, 2025

    By:

    /s/ Corey N. Fishman

     

     

     

    Corey N. Fishman
    Chief Executive Officer

     


    Get the next $ITRM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ITRM

    DatePrice TargetRatingAnalyst
    7/27/2021Sell → Hold
    Gabelli & Co.
    7/26/2021Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $ITRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dunne Michael W. bought $35,000 worth of Ordinary Shares (25,000 units at $1.40), increasing direct ownership by 28% to 113,754 units (SEC Form 4)

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      12/27/23 9:00:06 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dunne Michael W. bought $18,442 worth of Ordinary Shares (10,000 units at $1.84), increasing direct ownership by 13% to 88,754 units (SEC Form 4)

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      12/19/23 4:15:25 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dunne Michael W. bought $40,690 worth of Ordinary Shares (20,000 units at $2.03), increasing direct ownership by 34% to 78,754 units (SEC Form 4)

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      11/27/23 5:00:19 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    SEC Filings

    See more
    • Iterum Therapeutics plc filed SEC Form 8-K: Other Events

      8-K - Iterum Therapeutics plc (0001659323) (Filer)

      7/18/25 5:00:32 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Iterum Therapeutics plc

      PRE 14A - Iterum Therapeutics plc (0001659323) (Filer)

      7/18/25 8:00:16 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Iterum Therapeutics plc (0001659323) (Filer)

      6/11/25 7:15:25 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Coyne Christine

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      7/3/25 4:16:04 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Coyne Christine

      3 - Iterum Therapeutics plc (0001659323) (Issuer)

      7/3/25 4:15:09 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Whalen Joseph John

      3 - Iterum Therapeutics plc (0001659323) (Issuer)

      3/18/25 8:00:04 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Iterum Therapeutics upgraded by Gabelli & Co.

      Gabelli & Co. upgraded Iterum Therapeutics from Sell to Hold

      7/27/21 11:35:29 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics downgraded by HC Wainwright & Co.

      HC Wainwright & Co. downgraded Iterum Therapeutics from Buy to Neutral

      7/26/21 12:19:14 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics upgraded by Gabelli & Co

      Gabelli & Co upgraded Iterum Therapeutics from Sell to Hold

      5/28/21 8:38:55 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced that it has granted a non-statutory share option to purchase an aggregate of 200,000 ordinary shares of Iterum to Christine Coyne, Iterum's newly appointed Chief Commercial Officer. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation. The share option was granted effective July 1, 2025, with an exercise price of $0.97 per share, which is equal to t

      7/2/25 4:30:00 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth

      DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the United States, as well as future commercialization activities across new products and markets. "We are delighted to welcome Christine to the Iterum leadership team at such a pivotal time for the company," said

      6/30/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence

      DUBLIN and CHICAGO, June 25, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that NEJM Evidence published results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin® (amoxicillin/clavulanate) in adult women with uncomplicated urinary tract infections (uUTIs) https://evidence.nejm.org/

      6/25/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Leadership Updates

    Live Leadership Updates

    See more
    • Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth

      DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the United States, as well as future commercialization activities across new products and markets. "We are delighted to welcome Christine to the Iterum leadership team at such a pivotal time for the company," said

      6/30/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer

      DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical development and regulatory initiatives for Iterum. "We are thrilled that Sailaja is back at Iterum given her strong industry and operational leadership at a time when oral sulopenem is re-entering the clin

      12/13/21 8:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors

      Patrick Heron to leave the Board DUBLIN, Ireland and CHICAGO, March 16, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Beth P. Hecht to the Company’s Board of Directors replacing Patrick Heron, who announced he would be leaving the Board, effective as of March 12, 2021. Ms. Hecht will also serve as a member of the Audit Committee and Compensation Committee of the Board. “I want to thank Patrick for his leade

      3/16/21 7:30:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Financials

    Live finance-specific insights

    See more
    • Iterum Therapeutics Announces Partnership for Commercialization Services

      U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that it entered into a Product Commercialization Agreement (the "Agreement") with EVERSANA Life Science Services, LLC ("EVERSANA") for the commercialization of the Company's approved product, ORLYNVAHTM.   Pursuant to the Agreement, EVERSA

      6/11/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

      DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access

      5/6/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

      --ORLYNVAHTM Approved by FDA in Q4 2024— --Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2024. "While outreach to potential strategic partners is our priority and ongoing, we have begun pre-commercialization work to ensure ORLYNVAHTM is made available to patients as soon as possible to address the substantial u

      2/7/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Iterum Therapeutics plc

      SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)

      11/14/24 7:54:21 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Iterum Therapeutics plc

      SC 13G - Iterum Therapeutics plc (0001659323) (Subject)

      11/14/24 3:31:48 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Iterum Therapeutics plc

      SC 13G - Iterum Therapeutics plc (0001659323) (Subject)

      1/31/24 4:55:45 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care